Inflammation Response

Overview

Inflammation is the immune system's first line of defense against tissue injury, infection, and cellular damage. Characterized by the cardinal signs described by Celsus — redness (rubor), swelling (tumor), heat (calor), pain (dolor) — and later amended by Virchow to include loss of function (functio laesa), the inflammatory response serves to eliminate the cause of injury, clear damaged tissue, and initiate repair.

Acute inflammation is a protective, self-limiting process that resolves once the threat is eliminated and tissue repair begins. However, when resolution fails, chronic inflammation develops — a persistent, low-grade inflammatory state that drives tissue destruction and underlies many of the most prevalent diseases in modern medicine, including cardiovascular disease, type 2 diabetes, neurodegeneration, and cancer.

How It Works

Acute Inflammation

Recognition — Pattern recognition receptors (toll-like receptors and others) on tissue-resident immune cells (macrophages, mast cells, dendritic cells) detect pathogen-associated molecular patterns (PAMPs) from microbes or damage-associated molecular patterns (DAMPs) from injured cells.

Vascular response — Histamine and prostaglandins from mast cells cause arteriolar vasodilation (redness, heat) and increased vascular permeability (swelling). Plasma proteins including complement components and antibodies enter the tissue.

Leukocyte recruitment — Activated endothelium expresses selectins and integrins that capture circulating neutrophils. Chemokines (IL-8, MCP-1) create gradients guiding neutrophils to the injury site (chemotaxis). Neutrophils phagocytose pathogens and release antimicrobial agents.

Amplification — NF-kB signaling in macrophages drives production of pro-inflammatory cytokines (TNF-alpha, IL-1beta, IL-6), amplifying the response and recruiting additional immune cells.

Resolution — Lipid mediator class-switching produces pro-resolving molecules (lipoxins, resolvins, protectins) that halt neutrophil recruitment, promote neutrophil apoptosis, stimulate macrophage efferocytosis (clearance of dead cells), and transition the tissue toward repair.

Chronic Inflammation

When resolution mechanisms fail — due to persistent infection, autoimmune activation, metabolic stress (obesity), or continued exposure to irritants — chronic inflammation develops. Macrophages, lymphocytes, and fibroblasts dominate the chronic infiltrate. Ongoing tissue damage triggers simultaneous destruction and repair, often leading to fibrosis.

Key Molecular Mediators

• Prostaglandins and leukotrienes — Lipid mediators from arachidonic acid (COX and LOX pathways)
• Cytokines — TNF-alpha, IL-1beta, IL-6 (pro-inflammatory); IL-10, TGF-beta (anti-inflammatory)
• Complement system — Cascade producing opsonins, anaphylatoxins, and membrane attack complex
• Reactive oxygen species — Antimicrobial agents from the NADPH oxidase respiratory burst

Key Components

• NF-kB — Master transcription factor driving pro-inflammatory gene expression
• Macrophages — Central orchestrators transitioning between pro-inflammatory (M1) and pro-resolving (M2) phenotypes
• Neutrophils — First responders that phagocytose pathogens and form NETs
• Mast cells — Sentinel cells releasing histamine and initiating the vascular response
• Resolvins and lipoxins — Specialized pro-resolving mediators that terminate inflammation

Peptide Connections

Multiple peptides modulate the inflammatory response at various points:

KPV (Lys-Pro-Val) is a tripeptide derived from alpha-melanocyte-stimulating hormone (alpha-MSH) with potent anti-inflammatory activity. KPV inhibits NF-kB activation, reducing production of TNF-alpha, IL-1beta, and IL-6. Research has demonstrated KPV's efficacy in models of inflammatory bowel disease, where it reduces mucosal inflammation and promotes epithelial barrier restoration. KPV acts through the melanocortin system and has shown effects at very low concentrations.

BPC-157 modulates the inflammatory response by influencing both the acute phase and the transition to resolution. Research shows BPC-157 reduces excessive inflammatory cytokine production while promoting the angiogenic and proliferative processes necessary for tissue repair. BPC-157 also counteracts the tissue-damaging effects of NSAIDs, suggesting a modulatory rather than purely suppressive effect on inflammation.

LL-37 is a 37-amino-acid antimicrobial peptide (cathelicidin) that bridges innate immunity and inflammation. LL-37 directly kills bacteria, fungi, and enveloped viruses while also modulating the immune response by chemotactically recruiting neutrophils and monocytes, promoting wound healing, and modifying toll-like receptor signaling to prevent excessive inflammation.

Thymosin alpha-1 modulates inflammation through its immunoregulatory effects. By promoting dendritic cell maturation and regulatory T-cell differentiation, thymosin alpha-1 helps balance protective immunity against excessive inflammation, particularly relevant in sepsis and chronic inflammatory conditions.

Selank has demonstrated anti-inflammatory properties beyond its primary nootropic effects. Research shows Selank modulates cytokine expression patterns, reducing pro-inflammatory IL-6 while increasing anti-inflammatory IL-10, suggesting a shift toward inflammatory resolution.

Clinical Significance

Chronic inflammation is increasingly recognized as a unifying mechanism across major disease categories. "Inflammaging" — the chronic, sterile, low-grade inflammation associated with aging — contributes to cardiovascular disease, neurodegeneration, sarcopenia, and cancer. Senescent cells (cellular senescence) are a major source of inflammaging through the SASP.

Anti-inflammatory therapeutics range from NSAIDs (COX inhibitors) and corticosteroids to biologics targeting specific cytokines (anti-TNF, anti-IL-6, anti-IL-1). The recognition that inflammation resolution is an active process has opened therapeutic opportunities targeting pro-resolving pathways rather than simply suppressing pro-inflammatory ones.

Related Topics

• NF-kB Pathway — Master inflammatory transcription factor
• Immune Response — Adaptive immunity complementing innate inflammation
• Wound Healing Process — Follows successful inflammatory resolution
• Fibrosis Pathology — Consequence of chronic unresolved inflammation
• KPV — Anti-inflammatory tripeptide from alpha-MSH